Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma ...Middle East

SAN DIEGO, June 22, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted the Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous formulation of daratumumab, known...

Hence then, the article about halozyme announces janssen receives european marketing authorizations for darzalex daratumumab subcutaneous formulation for newly diagnosed systemic light chain amyloidosis and pre treated multiple myeloma was published today ( Tuesday 22/06/2021 - 09:16 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma )

Also on site :

• Firefighters fight police in France (VIDEOS)
• The NFL Names Its First-Ever 'Chief Kindness Officer' Ahead of Super Bowl LX
• 1990 Tearjerker Voted ‘Best Country Song’ of All Time